StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.40−0.41 (-7.06%)

Close on Nov 17, 2026Market cap $413.20MP/E –Yield –

Candel Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

No ev/ebitda figures for Candel Therapeutics

Candel Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Candel Therapeutics figures

See a number that looks wrong?